Mar 17, 2022 / 01:30PM GMT
Gena Wang - Barclays Bank PLC, Research Division - Research Analyst
Good morning, everyone. Welcome to Barclays Global Healthcare Conference. It is my great pleasure to introduce our next presenting company, Cellectis. With us today, we have Andre Choulika, Chief Executive Officer; and also Arthur Stril, our Chief Business Officer. Arthur, maybe I will hand over to you to give a intro for the company.
Arthur Stril - Cellectis S.A. - Chief Business Officer
Thank you, Gena, and good morning, everyone. I will just do a brief like 5 minutes overview of where we are and what's to be expected for this year, in particular, to let ample time for Gena to ask questions.
So we're primarily, as you know, a gene editing company, with a strong focus on allogeneic CAR T cells. We have currently 3 ongoing clinical trials in hematological malignancies with more than 30 patients dosed in our wholly-controlled programs as well as 5 additional trials with our licensed partners, Servier, Allogene, and very recently, Iovance, with more than 140 patients dosed.
We
Cellectis SA at Barclays Global Healthcare Conference Transcript
Mar 17, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers